
NYSEHealthcareMedical - Instruments & Supplies
最新数据
US$212.78
+US$0.10 · +0.05%
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
前收盘价
US$212.78
+US$0.10 · +0.05%
盘中时间采用ET。市场数据可能有所延迟。
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
日内区间
当前US$212.78
52周区间
当前US$212.78
盘中时间采用ET。市场数据可能有所延迟。
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
日内区间
当前US$212.78
52周区间
当前US$212.78
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 194.57亿 USD | 218.39亿 USD | 201.78亿 USD | 193.72亿 USD | 188.7亿 USD |
| 销货成本 | 102.43亿 USD | 119.15亿 USD | 110.53亿 USD | 112.02亿 USD | 103.93亿 USD |
| 毛利 | 92.14亿 USD | 99.24亿 USD | 91.25亿 USD | 81.7亿 USD | 84.77亿 USD |
| 研究与开发 | 9.88亿 USD | 12.64亿 USD | 11.9亿 USD | 12.37亿 USD | 12.56亿 USD |
| 销售、一般及管理费用 | 49.65亿 USD | 52.77亿 USD | 48.57亿 USD | 47.19亿 USD | 47.09亿 USD |
| 营业费用 | 69.58亿 USD | 73.47亿 USD | 67.28亿 USD | 60.59亿 USD | 61.95亿 USD |
| 利息收入 | 2700万 USD | 3800万 USD | 1.63亿 USD | 4900万 USD | 1600万 USD |
| 利息支出 | 5.64亿 USD | 6.13亿 USD | 5.28亿 USD | 4.52亿 USD | 3.98亿 USD |
| 折旧和摊销 | 22.38亿 USD | 24.62亿 USD | 22.86亿 USD | 22.88亿 USD | 22.29亿 USD |
| 营业利润 | 22.56亿 USD | 25.78亿 USD | 23.97亿 USD | 21.11亿 USD | 22.82亿 USD |
| 净利润 | 11.46亿 USD | 16.78亿 USD | 17.05亿 USD | 14.84亿 USD | 17.79亿 USD |
公司数据更新于 2026年11月22日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年2月10日 | 159:125 | — | — |
股票拆分 | 2022年4月1日 | 41:40 | — | — |
股票拆分 | 1998年8月21日 | 2:1 | — | — |
股票拆分 | 1996年8月16日 | 2:1 | — | — |
股票拆分 | 1993年3月1日 | 2:1 | — | — |
股票拆分 | 1986年3月3日 | 2:1 | — | — |
已生效 2026年2月10日
159:125
已生效 2022年4月1日
41:40
已生效 1998年8月21日
2:1
已生效 1996年8月16日
2:1
已生效 1993年3月1日
2:1
已生效 1986年3月3日
2:1
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T1116.54亿0.09%119.91万亿 JPY0.09%JP¥113,700-3.19%
Vanguard S&P 500 ETFVOO14.32亿0.08%1万亿 USD0.03%US$635.54-3.41%
Vanguard Morningstar Total Stock Market ETFVTI13.5亿0.07%6893亿 USD0.03%US$340.02-3.52%
Vanguard Morningstar Mid-Cap ETFVO11.51亿0.52%1074亿 USD0.03%US$76.25-2.22%
iShares Core S&P 500 ETFIVV7.8亿0.10%8034.1亿 USD0.03%US$693.71-3.52%
State Street SPDR S&P 500 ETFSPY7.04亿0.09%7563.79亿 USD0.09%US$689.81-3.64%
Vanguard Morningstar Value ETFVTV5.18亿0.19%1959亿 USD0.03%US$214.22-1.62%
State Street Health Care Select Sector SPDR ETFXLV4.23亿0.90%469.2亿 USD0.08%US$177.24-0.12%
State Street SPDR S&P 500 ETF1557.T
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Mid-Cap ETFVO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
State Street Health Care Select Sector SPDR ETFXLVAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。